Search - tctmd.com

Displaying 41 - 60 of 99

Sort: Relevancy | Date

News Conference News SCAI 2018

Largest CTO PCI Registry to Date Confirms Feasibility, in Expert Hands

Yael L. Maxwell

April 26, 2018

News Industry News

BioCardia Receives New Potency Assay Patent, Providing Further Protection to Autologous Cell Therapy Programs in Heart Failure and Refractory Angina

April 25, 2018

$Coronary Sinus Reducer Implantation for the Treatment of Chronic Refractory Angina$

Presentation

Coronary Sinus Reducer Implantation for the Treatment of Chronic Refractory Angina

April 16, 2018

$Positive Real-World Results for Coronary Sinus Reducer in Patients With Refractory Angina$

News Daily News

Positive Real-World Results for Coronary Sinus Reducer in Patients With Refractory Angina

Todd Neale

April 16, 2018

News Conference News TCT 2017

ORBITA: PCI Offers No Symptom Improvement Over Sham Procedure

Michael O'Riordan

November 02, 2017

$First Experience With the Coronary Sinus Reducer System for the Management of Refractory Angina in Patients Without Obstructive Coronary Artery Disease$

Presentation TCT 2017

First Experience With the Coronary Sinus Reducer System for the Management of Refractory Angina in Patients Without Obstructive Coronary Artery Disease

Presenter: Daniel Burkhoff, Samir R. Kapadia, Alaide Chieffo

November 01, 2017

$My Belief: Cell Therapy for Refractory Ischemia Is Ready for Daily Practice!$

Presentation TCT 2017

My Belief: Cell Therapy for Refractory Ischemia Is Ready for Daily Practice!

Presenter: Timothy D. Henry, Marc S. Penn

October 31, 2017

Presentation TCT 2017

Critical Limb Ischemia Update, and the STOP-PAD Trial

Presenter: Timothy D. Henry, Marc S. Penn, Mehdi H. Shishehbor

October 31, 2017

Presentation TCT 2017

New Strategies: Repetitive Injections

Presenter: Timothy D. Henry, Marc S. Penn, Ricardo Sanz-Ruiz

October 31, 2017

Presentation TCT 2017

New Trials: REGENT-VSEL

Presenter: Timothy D. Henry, Marc S. Penn, Wojtek Wojakowski

October 31, 2017

$Special Lecture: Treatment of Refractory Angina - Reducer-1 European Registry and US Approval Trial (With Discussion)$

Presentation TCT 2017

Special Lecture: Treatment of Refractory Angina - Reducer-1 European Registry and US Approval Trial (With Discussion)

Presenter: Philippe Genereux, Simon J. Walsh, Stefan Verheye

October 30, 2017

News Daily News

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Michael O'Riordan

August 14, 2017

$Access Denied: Stem Cell Therapy Shows Some Promise in Refractory Angina, but Patients Can’t Get It$

News Conference News SCAI 2017

Access Denied: Stem Cell Therapy Shows Some Promise in Refractory Angina, but Patients Can’t Get It

L.A. McKeown

May 19, 2017

News Daily News

ICTUS: No Benefit at 10 Years With Early Invasive Strategy in NSTE ACS Patients

Michael O'Riordan

April 11, 2017

News Conference News ACC 2017

DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions

Yael L. Maxwell

March 19, 2017

$The Coronary Sinus Reducer: A Device Based Therapy for Refractory Angina$

Presentation JIM 2017

The Coronary Sinus Reducer: A Device Based Therapy for Refractory Angina

Presenter: Francesco Giannini

February 10, 2017

News Industry News

FDA Grants Fast Track Designation To Angionetics' Generx Product Candidate, A One-Time Gene Therapy For Coronary Heart Disease

February 07, 2017

News Opinion Fellow Talk

Continuity Clinics: Indispensable to Medicine but Extraneous for Interventional Cardiology Fellows

Ankur Kalra

September 24, 2016

News Industry News

Angionetics' Generx® [Ad5FGF-4] Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease

September 12, 2016

News Daily News

新的分析未能证实 CTO PCI 成功和死亡率降低之间存在关联

Todd Neale

March 06, 2016

Advertisement

Largest CTO PCI Registry to Date Confirms Feasibility, in Expert Hands

BioCardia Receives New Potency Assay Patent, Providing Further Protection to Autologous Cell Therapy Programs in Heart Failure and Refractory Angina

Coronary Sinus Reducer Implantation for the Treatment of Chronic Refractory Angina

Positive Real-World Results for Coronary Sinus Reducer in Patients With Refractory Angina

ORBITA: PCI Offers No Symptom Improvement Over Sham Procedure

First Experience With the Coronary Sinus Reducer System for the Management of Refractory Angina in Patients Without Obstructive Coronary Artery Disease

My Belief: Cell Therapy for Refractory Ischemia Is Ready for Daily Practice!

Critical Limb Ischemia Update, and the STOP-PAD Trial

New Strategies: Repetitive Injections

New Trials: REGENT-VSEL

Special Lecture: Treatment of Refractory Angina - Reducer-1 European Registry and US Approval Trial (With Discussion)

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Access Denied: Stem Cell Therapy Shows Some Promise in Refractory Angina, but Patients Can’t Get It

ICTUS: No Benefit at 10 Years With Early Invasive Strategy in NSTE ACS Patients

DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions

The Coronary Sinus Reducer: A Device Based Therapy for Refractory Angina

FDA Grants Fast Track Designation To Angionetics' Generx Product Candidate, A One-Time Gene Therapy For Coronary Heart Disease

Continuity Clinics: Indispensable to Medicine but Extraneous for Interventional Cardiology Fellows

Angionetics' Generx® [Ad5FGF-4] Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease

新的分析未能证实 CTO PCI 成功和死亡率降低之间存在关联

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content